CYCLO THERAPEUTICS, INC.: basic earnings per share

What this measure means

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Exact concept: us-gaap:EarningsPerShareBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2021-01-01 to 2023-12-31. The SEC response was captured on 2026-09-21.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Related financial histories

• CYCLO THERAPEUTICS, INC.: total assets
• CYCLO THERAPEUTICS, INC.: stockholders equity
• CYCLO THERAPEUTICS, INC.: cash and cash equivalents
• CYCLO THERAPEUTICS, INC.: net income or loss
• CYCLO THERAPEUTICS, INC.: operating cash flow
• CYCLO THERAPEUTICS, INC.: capital expenditure payments
• CYCLO THERAPEUTICS, INC.: revenue
• CYCLO THERAPEUTICS, INC.: financing cash flow
• CYCLO THERAPEUTICS, INC.: investing cash flow
• CYCLO THERAPEUTICS, INC.: retained earnings or deficit
• CYCLO THERAPEUTICS, INC.: basic weighted-average shares
• CYCLO THERAPEUTICS, INC.: income tax expense or benefit
• CYCLO THERAPEUTICS, INC.: net property, plant and equipment
• CYCLO THERAPEUTICS, INC.: share-based compensation expense
• CYCLO THERAPEUTICS, INC.: operating income or loss
• CYCLO THERAPEUTICS, INC.: current assets
• CYCLO THERAPEUTICS, INC.: interest expense
• CYCLO THERAPEUTICS, INC.: current liabilities
• CYCLO THERAPEUTICS, INC.: net current accounts receivable
• CYCLO THERAPEUTICS, INC.: operating expenses
• CYCLO THERAPEUTICS, INC.: net inventory
• CYCLO THERAPEUTICS, INC.: research and development expense
• CYCLO THERAPEUTICS, INC.: common shares outstanding
• CYCLO THERAPEUTICS, INC.: additional paid-in capital
• CYCLO THERAPEUTICS, INC.: total equity including noncontrolling interests
• CYCLO THERAPEUTICS, INC.: operating lease right-of-use asset
• CYCLO THERAPEUTICS, INC.: long-term debt
• CYCLO THERAPEUTICS, INC.: gross property, plant and equipment
• CYCLO THERAPEUTICS, INC.: accumulated depreciation on property, plant and equipment
• CYCLO THERAPEUTICS, INC.: net intangible assets excluding goodwill
• CYCLO THERAPEUTICS, INC.: other noncurrent assets
• CYCLO THERAPEUTICS, INC.: net deferred tax assets
• CYCLO THERAPEUTICS, INC.: pre-tax income or loss from continuing operations
• CYCLO THERAPEUTICS, INC.: depreciation expense
• CYCLO THERAPEUTICS, INC.: depreciation, depletion and amortization
• CYCLO THERAPEUTICS, INC.: nonoperating income or expense
• CYCLO THERAPEUTICS, INC.: deferred income tax expense or benefit
• CYCLO THERAPEUTICS, INC.: interest paid, net
• CYCLO THERAPEUTICS, INC.: proceeds from issuing common stock
• CYCLO THERAPEUTICS, INC.: change in accounts receivable
• CYCLO THERAPEUTICS, INC.: change in inventories

Inspect the source

Entity

CYCLO THERAPEUTICS, INC. / CIK 0000922247

Captured

2026-09-21T17:17:43.874Z

SEC response SHA-256

00eb7fd40e8240f18174ace9c17e250765347f97ee2730b0222250298ac67de3

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000922247.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))